GlucoTrack says USPTO allows patent claims for implantable continuous blood glucose monitoring platform

GlucoTrack Inc

GlucoTrack Inc

GCTK

0.00
  • GlucoTrack received a USPTO Notice of Allowance for a patent application covering its fully implantable continuous blood glucose monitoring platform.
  • Allowed claims target an intravascular sensing lead linked to an electronics assembly, supporting long-term glucose monitoring in the vasculature.
  • The filing builds on three CBGM patents issued in late 2025, extending protection around the platform’s sensor architecture.
  • The system is designed for up to three years of monitoring with no wearable component, measuring glucose directly from blood to reduce lag.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607080800PRIMZONEFULLFEED9758633) on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.